2020

New Webinar: Alternative Strategies to Deliver Bladder Cancer Investigation During COVID-19 and Beyond

New Webinar: Alternative Strategies to Deliver Bladder Cancer Investigation During COVID-19 and Beyond

UroToday, a high profile news and education portal for urologists, have just released a new webinar focused on Cxbladder. In a discussion led by Neal Shore, MD, two influential urologists discuss their use of Cxbladder’s In-Home Sampling Programme and how it is currently being used by different urologists around the US to streamline patient care.

Webinar Introduction:

Many of the tests used to diagnose and detect bladder cancer involve invasive procedures. Non-invasive testing options are equally effective and can be applied in this COVID-19 environment where we want to limit patients needing to come into the clinics for tests. In this discussion Neal Shore, Sima Porten, and Tom Nifong discuss Cxbladder a non-invasive, urine-based laboratory test that measures the gene expression levels of five biomarkers in urine that effectively rule out or detect the presence of bladder cancer. The discussion provides a timely, efficient, and safer method, using Cxbladder to identify at-risk patients for non-muscle invasive bladder cancer (NMIBC) in the at-home setting.  

View the Webinar

« Back